4.6 Article

Cutting Edge: Enhanced Antitumor Immunity in ST8Sia6 Knockout Mice

Journal

JOURNAL OF IMMUNOLOGY
Volume 208, Issue 9, Pages 1845-1850

Publisher

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.2101165

Keywords

-

Categories

Funding

  1. Mayo Clinic Center of Biomedical Discovery
  2. National Institutes of Health/National Institute of Allergy and Infectious Diseases [R01CA243545, 2T32AI007425]

Ask authors/readers for more resources

This study reveals the role of ST8Sia6 in regulating antitumor immunity in immune cells. Loss of ST8Sia6 enhances immune response, promotes activation of macrophages and dendritic cells, and leads to a more inflammatory phenotype of regulatory T cells.
Inhibitory receptors have a critical role in the regulation of immunity. Siglecs are a family of primarily inhibitory receptors expressed by immune cells that recognize specific sialic acid modifications on cell surface glycans. Many tumors have increased sialic acid incorporation. Overexpression of the sialyltransferase ST8Sia6 on tumors led to altered immune responses and increased tumor growth. In this study, we examined the role of ST8Sia6 on immune cells in regulating antitumor immunity. ST8Sia6 knockout mice had an enhanced immune response to tumors. The loss of ST8Sia6 promoted an enhanced intratumoral activation of macrophages and dendritic cells, including upregulation of CD40. Intratumoral regulatory T cells exhibited a more inflammatory phenotype in ST8Sia6 knockout mice. Using adoptive transfer studies, the change in regulatory T cell phenotype was not cell intrinsic and depended on the loss of ST8Sia6 expression in APCs. Thus, ST8Sia6 generates ligands for Siglecs that dampen antitumor immunity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available